Primary liver cancer is a growing problem, particularly in Asia and parts of the developing world with a high prevalence of hepatitis C infection. New treatments that block the growth of tumor blood vessels give reason for hope and optimism for liver cancer patients.

Although there is an effective antiangiogenic drug available for liver cancer, it is important to remember that clinical trials are an important opportunity to gain access to even newer cutting edge cancer therapies. Clinical trials also contribute to the advancement of medical knowledge that can benefit future generations.